Christopher Ryan's most recent trade in Gevo Inc was a trade of 35,196 Common Stock done at an average price of $1.4 . Disclosure was reported to the exchange on June 12, 2026.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Gevo Inc | Christopher M. Ryan | President & COO | Sale of securities on an exchange or to another person at price $ 1.43 per share. | 12 Jun 2026 | 35,196 | 1,279,245 (8%) | 0% | 1.4 | 50,161 | Common Stock |
| Avalo Therapeutics Inc | Christopher Ryan Sullivan | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 13.10 per share. | 10 Jun 2026 | 138 | 40,773 | - | 13.1 | 1,808 | Common Stock |
| Gevo Inc | Christopher M. Ryan | President & COO | Sale of securities on an exchange or to another person at price $ 1.76 per share. | 27 May 2026 | 87,700 | 1,314,441 (9%) | 0% | 1.8 | 154,334 | Common Stock |
| Avalo Therapeutics Inc | Christopher Ryan Sullivan | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 May 2026 | 39,900 | 40,323 | - | 0 | Common Stock | |
| Avalo Therapeutics Inc | Christopher Ryan Sullivan | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 9.88 per share. | 07 May 2026 | 18,606 | 19,029 | - | 9.9 | 183,827 | Common Stock |
| Avalo Therapeutics Inc | Christopher Ryan Sullivan | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 07 May 2026 | 18,606 | 168,094 | - | - | Stock Option (Right to Buy) | |
| Avalo Therapeutics Inc | Christopher Ryan Sullivan | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 24.12 per share. | 07 May 2026 | 18,606 | 423 | - | 24.1 | 448,818 | Common Stock |
| Avalo Therapeutics Inc | Christopher Ryan Sullivan | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 06 May 2026 | 47,000 | 116,000 | - | - | Stock Option (Right to Buy) | |
| Avalo Therapeutics Inc | Christopher Ryan Sullivan | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 8.04 per share. | 06 May 2026 | 47,000 | 47,423 | - | 8.0 | 377,880 | Common Stock |
| Avalo Therapeutics Inc | Christopher Ryan Sullivan | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 18.55 per share. | 06 May 2026 | 13,834 | 33,589 | - | 18.6 | 256,655 | Common Stock |
| Avalo Therapeutics Inc | Christopher Ryan Sullivan | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 19.28 per share. | 06 May 2026 | 12,347 | 21,242 | - | 19.3 | 238,093 | Common Stock |
| Avalo Therapeutics Inc | Christopher Ryan Sullivan | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 21.37 per share. | 06 May 2026 | 9,219 | 9,323 | - | 21.4 | 197,008 | Common Stock |
| Avalo Therapeutics Inc | Christopher Ryan Sullivan | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 22.57 per share. | 06 May 2026 | 8,900 | 423 | - | 22.6 | 200,913 | Common Stock |
| Avalo Therapeutics Inc | Christopher Ryan Sullivan | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 20.76 per share. | 06 May 2026 | 2,700 | 18,542 | - | 20.8 | 56,052 | Common Stock |
| Avalo Therapeutics Inc | Christopher Ryan Sullivan | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 13.09 per share. | 29 Apr 2026 | 8,458 | 8,880 | - | 13.1 | 110,736 | Common Stock |
| Avalo Therapeutics Inc | Christopher Ryan Sullivan | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 13.23 per share. | 29 Apr 2026 | 8,457 | 423 | - | 13.2 | 111,853 | Common Stock |
| Bitcoin Depot Inc (Class A) | Christopher M. Ryan | General Counsel & Corp Sec | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Apr 2026 | 70,175 | 169,185 | - | 0 | Class A Common Stock | |
| Avalo Therapeutics Inc | Christopher Ryan Sullivan | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 16.83 per share. | 01 Apr 2026 | 7,479 | 25,318 | - | 16.8 | 125,841 | Common Stock |
| Avalo Therapeutics Inc | Christopher Ryan Sullivan | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 17.02 per share. | 01 Apr 2026 | 6,200 | 19,118 | - | 17.0 | 105,553 | Common Stock |
| Avalo Therapeutics Inc | Christopher Ryan Sullivan | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 17.57 per share. | 01 Apr 2026 | 1,780 | 17,338 | - | 17.6 | 31,270 | Common Stock |
| Avalo Therapeutics Inc | Christopher Ryan Sullivan | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 15.86 per share. | 01 Apr 2026 | 500 | 32,797 | - | 15.9 | 7,929 | Common Stock |
| Gevo Inc | Christopher Ryan M. | President & COO | Sale of securities on an exchange or to another person at price $ 2.76 per share. | 30 Mar 2026 | 100,000 | 1,431,938 (9%) | 0% | 2.8 | 275,740 | Common Stock |
| Bitcoin Depot Inc (Class A) | Christopher M. Ryan | General Counsel & Corp Sec | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Mar 2026 | 99,010 | 99,010 | - | 0 | Class A Common Stock | |
| Gevo Inc | Christopher Ryan M. | President & COO | Sale of securities on an exchange or to another person at price $ 2.96 per share. | 30 Mar 2026 | 29,797 | 1,402,141 (9%) | 0% | 3.0 | 88,175 | Common Stock |
| Avalo Therapeutics Inc | Christopher Ryan Sullivan | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Mar 2026 | 24,200 | 41,538 | - | - | Common Stock | |
| Avalo Therapeutics Inc | Christopher Ryan Sullivan | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Mar 2026 | 24,200 | 24,200 | - | - | Restricted Stock Units | |
| Avalo Therapeutics Inc | Christopher Ryan Sullivan | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 13.89 per share. | 28 Mar 2026 | 8,241 | 33,297 | - | 13.9 | 114,467 | Common Stock |
| Geo Grp Inc | Christopher D. Ryan | See Remarks | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Mar 2026 | 18,461 | 117,768 (0%) | 0% | 0 | Common Stock | |
| Geo Grp Inc | Christopher D. Ryan | See Remarks | Payment of exercise price or tax liability using portion of securities received from the company at price $ 14.35 per share. | 06 Mar 2026 | 15,449 | 102,319 (0%) | 0% | 14.3 | 221,693 | Common Stock |
| Geo Grp Inc | Christopher D. Ryan | See Remarks | Payment of exercise price or tax liability using portion of securities received from the company at price $ 15.29 per share. | 02 Mar 2026 | 914 | 64,552 (0%) | 0% | 15.3 | 13,975 | Common Stock |
| Avalo Therapeutics Inc | Christopher Ryan Sullivan | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Feb 2026 | 105,000 | 105,000 | - | - | Stock Option (Right to Buy) | |
| Geo Grp Inc | Christopher D. Ryan | Senior VP, Human Resources | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Feb 2026 | 13,500 | 110,088 | - | 0 | RESTRICTED STOCK | |
| Geo Grp Inc | Christopher D. Ryan | Senior VP, Human Resources | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Feb 2026 | 13,500 | 96,588 | - | 0 | RESTRICTED STOCK | |
| ATAI Life Sciences N.V. | Christopher Ryan Cave Barrett | See remarks | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Jan 2026 | 675,000 | 675,000 | - | - | Stock Option | |
| ATAI Life Sciences N.V. | Christopher Ryan Cave Barrett | See remarks | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Jan 2026 | 150,000 | 150,000 | - | - | Restricted Stock Units | |
| Avalo Therapeutics Inc | Christopher Ryan Sullivan | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 4.10 per share. | 10 Dec 2025 | 155 | 17,338 | - | 4.1 | 636 | Common Stock |
| Gevo Inc | Christopher Ryan | President & COO | Sale of securities on an exchange or to another person at price $ 2.82 per share. | 15 Oct 2025 | 100,000 | 1,531,938 (10%) | 0% | 2.8 | 281,870 | Common Stock |
| ATAI Life Sciences N.V. | Christopher Ryan Cave Barrett | See Remarks | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Oct 2025 | 175,000 | 175,000 | - | - | Stock Option | |
| Gevo Inc | Christopher Ryan | President & COO | Sale of securities on an exchange or to another person at price $ 1.63 per share. | 04 Sep 2025 | 1,683 | 1,631,938 (11%) | 0% | 1.6 | 2,742 | Common Stock |
| Gevo Inc | Christopher Ryan | President & COO | Sale of securities on an exchange or to another person at price $ 1.23 per share. | 05 Aug 2025 | 42,499 | 1,633,621 (11%) | 0% | 1.2 | 52,299 | Common Stock |
| Gevo Inc | Christopher Ryan | President & COO | Sale of securities on an exchange or to another person at price $ 1.25 per share. | 01 Aug 2025 | 43,964 | 1,676,120 (11%) | 0% | 1.3 | 55,082 | Common Stock |
| Gevo Inc | Christopher Ryan | President & COO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Jun 2025 | 626,618 | 626,618 | - | - | Stock Option | |
| Gevo Inc | Christopher Ryan | President & COO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Jun 2025 | 210,084 | 1,720,084 (11%) | 1% | 0 | Common Stock | |
| Gevo Inc | Christopher Ryan | President & COO | Sale of securities on an exchange or to another person at price $ 1.28 per share. | 30 May 2025 | 73,934 | 1,510,000 (10%) | 0% | 1.3 | 94,783 | Common Stock |
| Bitcoin Depot Inc (Class A) | Christopher M. Ryan | Chief Legal Officer | 01 Apr 2025 | 75,000 | 75,000 | - | 0 | Class A common stock | ||
| Avalo Therapeutics Inc | Christopher Ryan Sullivan | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Mar 2025 | 24,200 | 48,400 | - | - | Restricted Stock Units | |
| Avalo Therapeutics Inc | Christopher Ryan Sullivan | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Mar 2025 | 24,200 | 24,206 | - | - | Common Stock | |
| Avalo Therapeutics Inc | Christopher Ryan Sullivan | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 8.46 per share. | 28 Mar 2025 | 7,285 | 16,921 | - | 8.5 | 61,631 | Common Stock |
| Geo Grp Inc | Christopher D. Ryan | Senior VP, Human Resources | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Mar 2025 | 10,000 | 83,088 (0%) | 0% | 0 | Restricted Stock | |
| Geo Grp Inc | Christopher D. Ryan | Senior VP, Human Resources | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Mar 2025 | 10,000 | 73,088 (0%) | 0% | 0 | Restricted Stock | |
| Geo Grp Inc | Christopher D. Ryan | Senior VP, Human Resources | Payment of exercise price or tax liability using portion of securities received from the company at price $ 26.23 per share. | 03 Mar 2025 | 1,828 | 61,716 (0%) | 0% | 26.2 | 47,948 | Common Stock |
| Avalo Therapeutics Inc | Christopher Ryan Sullivan | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Jan 2025 | 163,000 | 163,000 | - | - | Stock Option (Right to Buy) | |
| Gevo Inc | Christopher Ryan | President & COO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Sep 2024 | 10,000 | 1,583,934 (10%) | 0% | 0 | Common Stock | |
| Gevo Inc | Christopher Ryan | President & COO | Sale of securities on an exchange or to another person at price $ 0.76 per share. | 22 Aug 2024 | 84,014 | 1,573,934 (10%) | 0% | 0.8 | 63,632 | Common Stock |
| Avalo Therapeutics Inc | Christopher Ryan Sullivan | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Aug 2024 | 186,700 | 186,700 | - | - | Stock Option (Right to Buy) | |
| Avalo Therapeutics Inc | Christopher Ryan Sullivan | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Aug 2024 | 72,600 | 72,600 | - | - | Restricted Stock Units | |
| Gevo Inc | Christopher Ryan | President & COO | Sale of securities on an exchange or to another person at price $ 0.51 per share. | 06 Aug 2024 | 46,608 | 1,657,948 (11%) | 0% | 0.5 | 23,579 | Common Stock |
| Gevo Inc | Christopher Ryan | President & COO | Sale of securities on an exchange or to another person at price $ 0.59 per share. | 31 Jul 2024 | 39,821 | 1,704,556 (11%) | 0% | 0.6 | 23,482 | Common Stock |
| Gevo Inc | Christopher Ryan | President & COO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 May 2024 | 550,000 | 550,000 | - | - | Stock Option | |
| Gevo Inc | Christopher Ryan | President & COO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 May 2024 | 550,000 | 1,744,377 (12%) | 3% | 0 | Common Stock | |
| Geo Grp Inc | Christopher D. Ryan | Senior VP, Human Resources | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2024 | 27,916 | 70,588 (0%) | 0% | 0 | Restricted Stock | |
| Geo Grp Inc | Christopher D. Ryan | Senior VP, Human Resources | Payment of exercise price or tax liability using portion of securities received from the company at price $ 12.09 per share. | 01 Mar 2024 | 2,742 | 56,044 (0%) | 0% | 12.1 | 33,151 | Common Stock |
| Gevo Inc | Christopher Ryan | President & COO | Sale of securities on an exchange or to another person at price $ 1.38 per share. | 23 Aug 2023 | 83,902 | 1,194,377 (8%) | 0% | 1.4 | 115,617 | Common Stock |
| Gevo Inc | Christopher Ryan | President & COO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Aug 2023 | 266,220 | 1,278,279 (8%) | 1% | 0 | Common Stock | |
| Gevo Inc | Christopher Ryan | President & COO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Aug 2023 | 266,220 | 266,220 | - | - | Stock Option | |
| Gevo Inc | Christopher Ryan | President & COO | Sale of securities on an exchange or to another person at price $ 1.65 per share. | 28 Jul 2023 | 36,551 | 1,012,059 (6%) | 0% | 1.6 | 60,265 | Common Stock |
| Avalo Therapeutics Inc | Christopher Ryan Sullivan | Chief Financial Officer | Purchase of securities on an exchange or from another person at price $ 3.42 per share. | 09 Jun 2023 | 511 | 1,262 | - | 3.4 | 1,748 | Common Stock |
| Avalo Therapeutics Inc | Christopher Ryan Sullivan | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 May 2023 | 40,000 | 40,000 | - | - | Stock Option (Right to Buy) | |
| Lakeland Ind Inc | Christopher J. Ryan | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Apr 2023 | 7,802 | 125,915 (1%) | 0% | 0 | Common Stock, par value $.01 per share | |
| Lakeland Ind Inc | Christopher J. Ryan | Director | Payment of exercise price or tax liability using portion of securities received from the company at price $ 12.55 per share. | 17 Apr 2023 | 2,569 | 123,346 (1%) | 0% | 12.6 | 32,241 | Common Stock, par value $.01 per share |
| Geo Grp Inc | Christopher D. Ryan | Senior VP, Human Resources | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2023 | 31,422 | 53,922 (0%) | 0% | 0 | Restricted Stock | |
| Geo Grp Inc | Christopher D. Ryan | Senior VP, Human Resources | Payment of exercise price or tax liability using portion of securities received from the company at price $ 9.07 per share. | 01 Mar 2023 | 3,351 | 47,536 (0%) | 0% | 9.1 | 30,394 | Common Stock |
| Avalo Therapeutics Inc | Christopher Ryan Sullivan | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Feb 2023 | 40,000 | 40,000 | - | - | Stock Option (Right to Buy) | |
| Lakeland Ind Inc | Christopher J. Ryan | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 Jan 2023 | 749 | 118,338 (1%) | 0% | - | Common Stock, par value $.01 per share | |
| Lakeland Ind Inc | Christopher J. Ryan | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 Jan 2023 | 749 | 749 | - | - | Restricted Stock Units | |
| Lakeland Ind Inc | Christopher J. Ryan | Director | Payment of exercise price or tax liability using portion of securities received from the company at price $ 14.48 per share. | 31 Jan 2023 | 225 | 118,113 (1%) | 0% | 14.5 | 3,258 | Common Stock, par value $.01 per share |
| Avalo Therapeutics Inc | Christopher Ryan Sullivan | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Oct 2022 | 25,000 | 25,000 | - | - | Stock Option (Right to Buy) | |
| Lakeland Ind Inc | Christopher J. Ryan | Director | Purchase of securities on an exchange or from another person at price $ 11.75 per share. | 13 Sep 2022 | 5,000 | 117,589 (1%) | 0% | 11.8 | 58,750 | Common Stock, par value $.01 per share |
| Gevo Inc | Christopher Ryan | President & COO | Sale of securities on an exchange or to another person at price $ 3.08 per share. | 22 Aug 2022 | 67,406 | 1,048,610 (7%) | 0% | 3.1 | 207,846 | Common Stock |
| Gevo Inc | Christopher Ryan | President & COO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Jul 2022 | 234,711 | 1,116,016 (7%) | 1% | 0 | Common Stock | |
| Gevo Inc | Christopher Ryan | President & COO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Jul 2022 | 158,116 | 158,116 | - | - | Stock Option | |
| Gevo Inc | Christopher Ryan | President & COO | Sale of securities on an exchange or to another person at price $ 2.53 per share. | 07 Jul 2022 | 79,145 | 881,305 (6%) | 0% | 2.5 | 200,237 | Common Stock |
| Gevo Inc | Christopher Ryan | President & COO | Sale of securities on an exchange or to another person at price $ 2.59 per share. | 21 Jun 2022 | 51,049 | 960,450 (6%) | 0% | 2.6 | 131,997 | Common Stock |
| Lakeland Ind Inc | Christopher J. Ryan | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Jun 2022 | 748 | 112,589 (1%) | 0% | - | Common Stock, par value $.01 per share | |
| Lakeland Ind Inc | Christopher J. Ryan | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Jun 2022 | 748 | 1,498 | - | - | Restricted Stock Units | |
| Lakeland Ind Inc | Christopher J. Ryan | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Jun 2022 | 3,918 | 111,841 (1%) | 0% | 0 | Common Stock, par value $.01 per share | |
| Lakeland Ind Inc | Christopher J. Ryan | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Apr 2022 | 27,686 | 117,890 (1%) | 0% | 0 | Common Stock, par value $.01 per share | |
| Lakeland Ind Inc | Christopher J. Ryan | Director | Payment of exercise price or tax liability using portion of securities received from the company at price $ 17.16 per share. | 21 Apr 2022 | 9,967 | 107,923 (1%) | 0% | 17.2 | 171,034 | Common Stock, par value $.01 per share |
| Avalo Therapeutics Inc | Christopher Ryan Sullivan | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Mar 2022 | 400,000 | 400,000 | - | - | Stock Option (Right to Buy) | |
| Avalo Therapeutics Inc | Christopher Ryan Sullivan | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Mar 2022 | 50,000 | 50,000 | - | - | Stock Option (Right to Buy) | |
| Avalo Therapeutics Inc | Christopher Ryan Sullivan | Chief Accounting Officer | Purchase of securities on an exchange or from another person at price $ 1.57 per share. | 10 Dec 2021 | 955 | 9,004 | - | 1.6 | 1,499 | Common Stock |
| Gevo Inc | Christopher Ryan | President & COO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Aug 2021 | 522,900 | 522,900 | - | - | Stock Option | |
| Gevo Inc | Christopher Ryan | President & COO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Aug 2021 | 522,900 | 1,011,499 (6%) | 3% | 0 | Common Stock |